BridgeBio Pharma (BBIO) Stock Forecast, Price Target & Predictions
BBIO Stock Forecast
BridgeBio Pharma stock forecast is as follows: an average price target of $45.00 (represents a 78.57% upside from BBIO’s last price of $25.20) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
BBIO Price Target
The average price target for BridgeBio Pharma (BBIO) is $45.00 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $58.00 to $19.00. This represents a potential 78.57% upside from BBIO's last price of $25.20.
BBIO Analyst Ratings
According to 10 Wall Street analysts, BridgeBio Pharma's rating consensus is 'Buy'. The analyst rating breakdown for BBIO stock is 0 'Strong Buy' (0.00%), 9 'Buy' (90.00%), 1 'Hold' (10.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
BridgeBio Pharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 24, 2024 | David Lebowitz | Citigroup | $45.00 | $24.17 | 86.18% | 78.57% |
| Oct 17, 2024 | Mani Foroohar | Leerink Partners | $46.00 | $26.34 | 74.64% | 82.54% |
| Sep 11, 2024 | Biren Amin | Piper Sandler | $46.00 | $28.78 | 59.83% | 82.54% |
| Sep 03, 2024 | Salim Syed | Mizuho Securities | $53.00 | $29.92 | 77.14% | 110.32% |
| Jun 24, 2024 | Danielle Brill | Raymond James | $46.00 | $22.64 | 103.14% | 82.54% |
| Jun 05, 2024 | Kostas Biliouris | BMO Capital | $37.00 | $26.93 | 37.42% | 46.83% |
| Jun 05, 2024 | Tiago Fauth | Wells Fargo | $58.00 | $27.13 | 113.79% | 130.16% |
| May 30, 2024 | Paul Choi | Goldman Sachs | $50.00 | $27.61 | 81.09% | 98.41% |
| May 28, 2024 | Eliana Merle | UBS | $47.00 | $27.94 | 68.22% | 86.51% |
| May 20, 2024 | Raghuram Selvaraju | H.C. Wainwright | $43.00 | $30.09 | 42.90% | 70.63% |
The latest BridgeBio Pharma stock forecast, released on Oct 24, 2024 by David Lebowitz from Citigroup, set a price target of $45.00, which represents a 86.18% increase from the stock price at the time of the forecast ($24.17), and a 78.57% increase from BBIO last price ($25.20).
BridgeBio Pharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 4 | 11 |
| Avg Price Target | $45.50 | $47.50 | $47.36 |
| Last Closing Price | $25.20 | $25.20 | $25.20 |
| Upside/Downside | 80.56% | 88.49% | 87.94% |
In the current month, the average price target of BridgeBio Pharma stock is $45.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 80.56% increase as opposed to BridgeBio Pharma's last price of $25.20. This month's average price target is down -4.21% compared to last quarter, and down -3.93% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 24, 2024 | Citigroup | Buy | Buy | Hold |
| Oct 02, 2024 | Oppenheimer | - | Perform | Initialise |
| Sep 24, 2024 | BMO Capital | Market Perform | Market Perform | Hold |
| Sep 11, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 04, 2024 | Piper Sandler | - | Overweight | Initialise |
| Sep 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 24, 2024 | Raymond James | Outperform | Outperform | Hold |
| Jun 24, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Jun 10, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jun 05, 2024 | BMO Capital | Outperform | Outperform | Hold |
BridgeBio Pharma's last stock rating was published by Citigroup on Oct 24, 2024. The company gave BBIO a "Buy" rating, the same as its previous rate.
BridgeBio Pharma Financial Forecast
BridgeBio Pharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $4.09M | $1.64M | $1.83M | $1.87M | $338.00K | $73.75M | $1.69M | $12.89M | $2.34M | $54.02M | $462.00K | $122.00K | $8.13M |
| Avg Forecast | $53.43M | $47.14M | $47.33M | $27.40M | $23.50M | $1.56M | $3.96M | $7.26M | $4.55M | $3.62M | $2.99M | $3.23M | $4.52M | $4.09M | $27.19M | $4.70M | $21.56M | $15.80M | $28.49M | $27.51M | $16.93M | $10.75M |
| High Forecast | $53.43M | $47.14M | $47.33M | $27.40M | $23.50M | $6.84M | $3.96M | $7.26M | $7.30M | $3.62M | $2.99M | $3.23M | $4.52M | $4.09M | $27.19M | $4.70M | $21.56M | $15.80M | $28.49M | $27.51M | $16.93M | $10.75M |
| Low Forecast | $53.43M | $47.14M | $47.33M | $27.40M | $23.50M | $314.32K | $3.96M | $7.26M | $995.98K | $3.62M | $2.99M | $3.23M | $4.52M | $4.09M | $27.19M | $4.70M | $21.56M | $15.80M | $28.49M | $27.51M | $16.93M | $10.75M |
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 2 | 4 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 6 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.13% | 0.55% | 0.57% | 0.41% | 0.08% | 2.71% | 0.36% | 0.60% | 0.15% | 1.90% | 0.02% | 0.01% | 0.76% |
BridgeBio Pharma's average Quarter revenue forecast for Dec 23 based on 4 analysts is $4.55M, with a low forecast of $995.98K, and a high forecast of $7.30M. BBIO's average Quarter revenue forecast represents a 11.18% increase compared to the company's last Quarter revenue of $4.09M (Sep 23).
BridgeBio Pharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 2 | 4 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 6 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-157.69M | $-146.10M | $-117.61M | $-112.89M | $-113.71M | $27.70M | $-156.44M | $-130.52M | $-144.60M | $-82.82M | $-151.98M | $-109.02M | $-104.93M |
| Avg Forecast | $-53.43M | $-47.14M | $-47.33M | $-27.40M | $-23.50M | $-1.56M | $-3.96M | $-119.34M | $-4.55M | $-3.62M | $-2.99M | $-127.64M | $-120.47M | $-4.09M | $-27.19M | $-136.51M | $-21.56M | $-15.80M | $-28.49M | $-67.77M | $-16.93M | $-10.75M |
| High Forecast | $-53.43M | $-47.14M | $-47.33M | $-27.40M | $-23.50M | $-314.32K | $-3.96M | $-95.47M | $-995.98K | $-3.62M | $-2.99M | $-102.11M | $-96.37M | $-4.09M | $-27.19M | $-109.21M | $-21.56M | $-15.80M | $-28.49M | $-54.22M | $-16.93M | $-10.75M |
| Low Forecast | $-53.43M | $-47.14M | $-47.33M | $-27.40M | $-23.50M | $-6.84M | $-3.96M | $-143.21M | $-7.30M | $-3.62M | $-2.99M | $-153.17M | $-144.56M | $-4.09M | $-27.19M | $-163.81M | $-21.56M | $-15.80M | $-28.49M | $-81.33M | $-16.93M | $-10.75M |
| Surprise % | - | - | - | - | - | - | - | - | - | 43.51% | 48.81% | 0.92% | 0.94% | 27.83% | -1.02% | 1.15% | 6.05% | 9.15% | 2.91% | 2.24% | 6.44% | 9.76% |
7 analysts predict BBIO's average Quarter EBITDA for Sep 22 to be $-4.09M, with a high of $-4.09M and a low of $-4.09M. This is -114.75% lower than BridgeBio Pharma's previous annual EBITDA (Jun 22) of $27.70M.
BridgeBio Pharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 2 | 4 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 6 |
| Net Income | - | - | - | - | - | - | - | - | - | $-177.00M | $-157.90M | $-176.85M | $-155.97M | $-148.42M | $59.37M | $-246.71M | $-167.42M | $-155.94M | $-96.35M | $-163.08M | $-119.98M | $-115.86M |
| Avg Forecast | $-160.86M | $-166.01M | $-158.62M | $-175.50M | $-172.89M | $-184.99M | $-187.23M | $-134.57M | $-162.99M | $-148.83M | $-149.84M | $-143.93M | $-135.84M | $-181.61M | $-104.42M | $-153.93M | $-165.43M | $-171.56M | $-182.26M | $-72.72M | $-161.35M | $-168.41M |
| High Forecast | $-160.86M | $-166.01M | $-158.62M | $-175.50M | $-172.89M | $-168.83M | $-187.23M | $-107.66M | $-137.25M | $-115.76M | $-149.84M | $-115.14M | $-108.67M | $-181.61M | $-104.42M | $-123.15M | $-165.43M | $-171.56M | $-182.26M | $-58.18M | $-161.35M | $-168.41M |
| Low Forecast | $-160.86M | $-166.01M | $-158.62M | $-175.50M | $-172.89M | $-202.96M | $-187.23M | $-161.49M | $-199.02M | $-183.74M | $-149.84M | $-172.71M | $-163.01M | $-181.61M | $-104.42M | $-184.72M | $-165.43M | $-171.56M | $-182.26M | $-87.27M | $-161.35M | $-168.41M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.19% | 1.05% | 1.23% | 1.15% | 0.82% | -0.57% | 1.60% | 1.01% | 0.91% | 0.53% | 2.24% | 0.74% | 0.69% |
BridgeBio Pharma's average Quarter net income forecast for Sep 22 is $-181.61M, with a range of $-181.61M to $-181.61M. BBIO's average Quarter net income forecast represents a -405.91% decrease compared to the company's last Quarter net income of $59.37M (Jun 22).
BridgeBio Pharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 2 | 4 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 6 |
| SG&A | - | - | - | - | - | - | - | - | - | $35.78M | $36.12M | $31.11M | $31.86M | $31.19M | $36.43M | $43.71M | $54.75M | $46.08M | $45.97M | $45.41M | $37.44M | $36.02M |
| Avg Forecast | $435.70M | $384.44M | $386.02M | $223.47M | $191.64M | $12.75M | $32.30M | $59.20M | $37.09M | $29.56M | $24.41M | $26.35M | $36.90M | $33.33M | $221.73M | $38.29M | $175.85M | $128.85M | $232.30M | $20.25M | $138.07M | $87.67M |
| High Forecast | $435.70M | $384.44M | $386.02M | $223.47M | $191.64M | $55.75M | $32.30M | $59.20M | $59.56M | $29.56M | $24.41M | $26.35M | $36.90M | $33.33M | $221.73M | $38.29M | $175.85M | $128.85M | $232.30M | $24.30M | $138.07M | $87.67M |
| Low Forecast | $435.70M | $384.44M | $386.02M | $223.47M | $191.64M | $2.56M | $32.30M | $59.20M | $8.12M | $29.56M | $24.41M | $26.35M | $36.90M | $33.33M | $221.73M | $38.29M | $175.85M | $128.85M | $232.30M | $16.20M | $138.07M | $87.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.21% | 1.48% | 1.18% | 0.86% | 0.94% | 0.16% | 1.14% | 0.31% | 0.36% | 0.20% | 2.24% | 0.27% | 0.41% |
BridgeBio Pharma's average Quarter SG&A projection for Dec 23 is $37.09M, based on 4 Wall Street analysts, with a range of $8.12M to $59.56M. The forecast indicates a 3.67% rise compared to BBIO last annual SG&A of $35.78M (Sep 23).
BridgeBio Pharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 2 | 4 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 6 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $-1.16 | $-1.04 | $-1.00 | $0.40 | $-1.69 | $-1.15 | $-1.06 | $-0.66 | $-1.18 | $-1.01 | $-0.98 |
| Avg Forecast | $-0.86 | $-0.89 | $-0.85 | $-0.94 | $-0.92 | $-0.99 | $-1.00 | $-0.74 | $-0.87 | $-0.79 | $-0.80 | $-0.82 | $-0.84 | $-0.97 | $-0.56 | $-1.09 | $-0.88 | $-0.91 | $-0.97 | $-0.75 | $-0.86 | $-0.90 |
| High Forecast | $-0.86 | $-0.89 | $-0.85 | $-0.94 | $-0.92 | $-0.90 | $-1.00 | $-0.74 | $-0.73 | $-0.62 | $-0.80 | $-0.82 | $-0.84 | $-0.97 | $-0.56 | $-1.09 | $-0.88 | $-0.91 | $-0.97 | $-0.75 | $-0.86 | $-0.90 |
| Low Forecast | $-0.86 | $-0.89 | $-0.85 | $-0.94 | $-0.92 | $-1.08 | $-1.00 | $-0.74 | $-1.06 | $-0.98 | $-0.80 | $-0.82 | $-0.84 | $-0.97 | $-0.56 | $-1.09 | $-0.88 | $-0.91 | $-0.97 | $-0.75 | $-0.86 | $-0.90 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 1.41% | 1.24% | 1.03% | -0.72% | 1.56% | 1.30% | 1.16% | 0.68% | 1.57% | 1.17% | 1.09% |
According to 7 Wall Street analysts, BridgeBio Pharma's projected average Quarter EPS for Sep 22 is $-0.97, with a low estimate of $-0.97 and a high estimate of $-0.97. This represents a -342.03% decrease compared to BBIO previous annual EPS of $0.40 (Jun 22).
BridgeBio Pharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.53 | $3.67 | 592.45% | Buy |
| INZY | Inozyme Pharma | $4.42 | $14.67 | 231.90% | Buy |
| APLS | Apellis Pharmaceuticals | $28.56 | $76.13 | 166.56% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.95 | $7.00 | 137.29% | Buy |
| TERN | Terns Pharmaceuticals | $7.10 | $14.25 | 100.70% | Buy |
| BBIO | BridgeBio Pharma | $25.20 | $45.00 | 78.57% | Buy |
| BPMC | Blueprint Medicines | $91.88 | $109.71 | 19.41% | Buy |
| PTCT | PTC Therapeutics | $40.39 | $46.50 | 15.13% | Hold |
| KRYS | Krystal Biotech | $170.85 | $191.00 | 11.79% | Buy |
| MDGL | Madrigal Pharmaceuticals | $331.32 | $315.75 | -4.70% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.70 | $5.33 | -6.49% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
BBIO Forecast FAQ
Is BridgeBio Pharma a good buy?
Yes, according to 10 Wall Street analysts, BridgeBio Pharma (BBIO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 90.00% of BBIO's total ratings.
What is BBIO's price target?
BridgeBio Pharma (BBIO) average price target is $45 with a range of $19 to $58, implying a 78.57% from its last price of $25.2. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will BridgeBio Pharma stock go up soon?
According to Wall Street analysts' prediction for BBIO stock, the company can go up by 78.57% (from the last price of $25.2 to the average price target of $45), up by 130.16% based on the highest stock price target, and down by -24.60% based on the lowest stock price target.
Can BridgeBio Pharma stock reach $40?
BBIO's average twelve months analyst stock price target of $45 supports the claim that BridgeBio Pharma can reach $40 in the near future.
What is BridgeBio Pharma's current price target trend?
2 Wall Street analysts forecast a $45.5 price target for BridgeBio Pharma (BBIO) this month, up 80.56% from its last price of $25.2. Compared to the last 3 and 12 months, the average price target increased by 88.49% and increased by 87.94%, respectively.
What are BridgeBio Pharma's analysts' financial forecasts?
BridgeBio Pharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $36.28M (high $41.56M, low $35.03M), average EBITDA is $-148M (high $-123M, low $-178M), average net income is $-680M (high $-637M, low $-725M), average SG&A $295.9M (high $338.9M, low $285.7M), and average EPS is $-3.643 (high $-3.557, low $-3.738). BBIO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $175.3M (high $175.3M, low $175.3M), average EBITDA is $-175M (high $-175M, low $-175M), average net income is $-661M (high $-661M, low $-661M), average SG&A $1.43B (high $1.43B, low $1.43B), and average EPS is $-3.524 (high $-3.524, low $-3.524).
Did the BBIO's actual financial results beat the analysts' financial forecasts?
Based on BridgeBio Pharma's last annual report (Dec 2022), the company's revenue was $77.65M, beating the average analysts forecast of $40.5M by 91.74%. Apple's EBITDA was $-354M, beating the average prediction of $-288M by 22.70%. The company's net income was $-494M, missing the average estimation of $-576M by -14.21%. Apple's SG&A was $143.19M, missing the average forecast of $330.25M by -56.64%. Lastly, the company's EPS was $-3.35, missing the average prediction of $-3.449 by -2.88%. In terms of the last quarterly report (Sep 2023), BridgeBio Pharma's revenue was $4.09M, beating the average analysts' forecast of $3.62M by 12.87%. The company's EBITDA was $-158M, beating the average prediction of $-3.625M by 4250.58%. BridgeBio Pharma's net income was $-177M, beating the average estimation of $-149M by 18.93%. The company's SG&A was $35.78M, beating the average forecast of $29.56M by 21.04%. Lastly, the company's EPS was $-0.0011, missing the average prediction of $-0.793 by -99.86%